<SEC-DOCUMENT>0001628280-23-038227.txt : 20231109
<SEC-HEADER>0001628280-23-038227.hdr.sgml : 20231109
<ACCEPTANCE-DATETIME>20231109160745
ACCESSION NUMBER:		0001628280-23-038227
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231109
DATE AS OF CHANGE:		20231109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		231392390

	BUSINESS ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		(650) 649-1004

	MAIL ADDRESS:	
		STREET 1:		100 CARDINAL WAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>advm-20231109.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:8ba87662-ad53-413a-ac26-122ea970731c,g:b4d8d8ae-b05c-45ce-b683-71836c355ca9,d:64b413fb243b465692cccef997b5b42c--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20231109</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501756</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20231109.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-09</xbrli:startDate><xbrli:endDate>2023-11-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i64b413fb243b465692cccef997b5b42c_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 9, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.586%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.296%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36579</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">20-5258327</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">100 Cardinal Way</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">94063</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">656-9323</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.438%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a&#8211;12 under the Exchange Act (17 CFR 240.14a&#8211;12)</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d&#8211;2(b) under the Exchange Act (17 CFR 240.14d&#8211;2(b))</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e&#8211;4(c) under the Exchange Act (17 CFR 240.13e&#8211;4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ADVM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i64b413fb243b465692cccef997b5b42c_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On November 9, 2023, Adverum Biotechnologies, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The information in this report, including the exhibit hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Adverum Biotechnologies, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="i64b413fb243b465692cccef997b5b42c_10"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit991_110923pressrele.htm">Press Release dated November 9, 2023, announcing Adverum Biotechnologies, Inc. financial results for the quarter ended September 30, 2023, and providing a corporate update.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The cover page of this report has been formatted in Inline XBRL.</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i64b413fb243b465692cccef997b5b42c_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:47.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.178%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Adverum Biotechnologies, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date: November 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laurent Fischer, M.D. <br/>President and Chief Executive Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991_110923pressrele.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3b6d68d5e1b342f4917e439c7fe8cbac_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="logo.jpg" src="logo.jpg" style="height:102px;margin-bottom:5pt;vertical-align:text-bottom;width:306px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:108%">- </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%">Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels observed in the OPTIC trial -</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%">- Reported OPTIC long-term follow-up data demonstrating that patients continue to experience substantial, long-term benefit from Ixo-vec through 3 years of follow-up -</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%">- Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 -</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%">- Cash runway projected into 2025 - </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">REDWOOD CITY, Calif., November 9, 2023 - </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Adverum Biotechnologies, Inc. (Nasdaq&#58; ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8220;In our OPTIC presentation at AAO, we&#8217;ve built upon our industry leading dataset in wet AMD gene therapy,&#8221; stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies. &#8220;Patients who have received a single intravitreal injection of Ixo-vec continue to receive benefit through three years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden, with half of the patients remaining entirely free of injections. Our first data presented from the LUNA trial, reported during the third quarter, reinforced what we&#8217;ve learned from both the ongoing OPTIC extension trial and our nonclinical NHP data, and suggests that both the 2E11 and 6E10 vg&#47;eye doses of Ixo-vec produce aflibercept levels that are associated with significant clinical activity. We look forward to presenting our initial safety and efficacy data from our ongoing LUNA trial during the fourth quarter, and ultimately to bringing the potential of this transformative therapy to patients with wet AMD.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Recent Pipeline Highlights&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Aflibercept Protein Level Data from Ongoing LUNA Phase 2 Trial&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">In September 2023, the company announced aflibercept protein data suggesting that Ixo-vec at the 2E11 and 6E10 doses deliver similar levels of aflibercept that are both within the therapeutically active range based on OPTIC and non-human primate data.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Long-Term Ixo-vec OPTIC Trial Data at AAO 2023&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">In November 2023, the company announced 3-year data from the OPTIC extension study of patients with wet AMD during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting in San Francisco, California. </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">Patients in the OPTIC extension trial continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">Patients at the 2E11 dose had an 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 dose receiving zero supplemental injections through three years.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">Aflibercept protein levels have been sustained through follow-up, which is up to 4.5 years post-treatment.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">BCVA was maintained and CST was improved through 3 years.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%;padding-left:14.25pt">Ixo-vec was generally well tolerated with the most common adverse event of dose-dependent inflammation that was responsive to topical corticosteroids.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Scientific Meeting Presentations&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">In October 2023, Adverum showcased non-clinical data in two presentations at the European Society of Cell and Gene Therapy 2023 Annual Meeting. </font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:14.25pt">Oral Presentation Title&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> Dose-dependent inflammation signatures following Ixo-vec administration in non-human primates</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:14.25pt">Poster Presentation Title&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> Functional and molecular evaluation of IVT AAV gene therapy vectors for the treatment of GA</font></div><div style="margin-top:6pt;padding-left:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Corporate Updates&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Appointment of Andrew Ramelmeier, Ph.D. as Chief Technology Officer&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> In August 2023, the company announced the appointment of Dr. Andrew Ramelmeier, as Chief Technology Officer, to lead Adverum&#8217;s technology and operations organization, including process and assay development for Ixo-vec. Dr. Ramelmeier has over three decades of experience in drug development, clinical and commercial CMC, and quality controls for gene and cell therapy products.  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:108%;padding-left:12.53pt">Appointment of C. David Nicholson, Ph.D. to Board of Directors&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> In November 2023, the company announced the appointment of C. David Nicholson, Ph.D., as an independent member of its Board of Directors, effective November 3, 2023. Dr. Nicholson brings over forty years of pharmaceutical experience, a proven track record in drug development, and deep experience in ophthalmology, most recently as chief research and development officer at Allergan. </font></div><div style="margin-top:6pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Anticipated Milestones</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%;padding-left:14.15pt">Q4 2023&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">LUNA preliminary efficacy and safety data.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%;padding-left:12.53pt">Mid-2024&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Additional LUNA data, including the 26-week interim analysis.  </font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Financial Results for the Three Months Ended September 30, 2023</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Cash, cash equivalents and short-term investments</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $117.1 million as of September 30, 2023, compared to $185.6 million as of December 31, 2022. Adverum expects the September 30, 2023 cash position to fund operations into 2025.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Research and development expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $20.7 million for the three months ended September 30, 2023, compared to $23.8 million for the same period in 2022. Research and development costs decreased due to lower compensation, material production and bioanalytics expenses, partially offset by higher facilities related expenses. Stock-based compensation expense included in research and development expenses was $1.2 million for the third quarter of 2023.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">General and administrative expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> were $13.8 million for the three months ended September 30, 2023, compared to $17.2 million for the same period in 2022. General and administrative costs decreased due to reversal of sublease income in prior year and lower compensation expense, partially offset by higher professional services expense. Stock-based compensation expense included in general and administrative expenses was $3.2 million for the third quarter of 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:12.53pt">Net Loss</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> was $32.9 million, or $0.33 per basic and diluted share, for the three months ended September 30, 2023, compared to $40.1 million, or $0.40 per basic and diluted share, for the same period in 2022.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">About Wet Age-Related Macular Degeneration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%"> </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Wet AMD, also known as neovascular AMD or nAMD, is a VEGF driven advanced form of AMD affecting approximately 10% of patients living with AMD associated with the build-up of fluid in the macula and the retina. Wet AMD is a leading cause of blindness in people over 65 years of age, with approximately 20 million individuals worldwide living with this condition. New cases of wet AMD are expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately 10% of those cases. Additionally, wet AMD is a bilateral disease, and incidence of nAMD in the second eye is up to 42% in the first two to three years. The current standard of care requires frequent life-long repeated bolus injections of anti-VEGF in the eye. IVT gene therapy has the promise to preserve vision and reduce most or all injections for the life of the patient by delivering stable therapeutic levels of anti-VEGF to control macular fluid.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">About Ixo-vec in Wet AMD</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Adverum is developing ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), its clinical-stage gene therapy product candidate, for the treatment of wet AMD. Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require surgery to administer the gene therapy under the retina (sub-retinal approach), Ixo-vec is designed to be administered as a one-time IVT injection in the physician&#8217;s office, deliver long-term efficacy, reduce the burden of frequent anti-vascular endothelial growth factor (VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD. In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration granted Fast Track designation for Ixo-vec for the treatment of wet AMD. Ixo-vec has also received PRIME designation from the European Medicines Agency and the Innovation Passport from the United Kingdom&#8217;s Medicines and Healthcare Products Regulatory Agency for the treatment of wet AMD.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">About Adverum Biotechnologies</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Adverum Biotechnologies (NASDAQ&#58; ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians&#8217; offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;text-decoration:underline">www.adverum.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:108%">Forward-looking Statements</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:108%">Statements contained in this press release regarding events or results that may occur in the future are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements regarding the potential benefits of Ixo-vec in the treatment of wet AMD, the design of the LUNA trial, and anticipated preliminary and interim efficacy and safety data from the LUNA trial. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including risks inherent to, without limitation&#58; Adverum&#8217;s novel technology, which makes it difficult to predict the timing of commencement and completion of clinical trials&#59; regulatory uncertainties&#59; enrollment uncertainties&#59; the results of early clinical trials not always being predictive of future clinical trials and results&#59; and the potential for future complications or side effects in connection with use of Ixo-vec. Additional risks and uncertainties facing Adverum are set forth under the caption &#8220;Risk Factors&#8221; and elsewhere in Adverum&#8217;s Securities and Exchange Commission (SEC) filings and reports, including Adverum&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 filed with the SEC on August 10, 2023. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Corporate, Investor and Media Inquiries</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">E&#58; </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;text-decoration:underline">ir&#64;adverum.com </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.030%"><tr><td style="width:1.0%"></td><td style="width:51.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consolidated Balance Sheets</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands)</font></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Unaudited)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">September 30</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">December 31</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Unaudited)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(1)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Assets</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current assets&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">105,366&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">68,431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Short-term investments</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11,716</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">117,158</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prepaid expenses and other current assets</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7,514</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5,006</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:40pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total current assets</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">124,596</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">190,595</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment, net</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15,497</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">34,927</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating lease right-of-use asset</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">52,757</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">78,934</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Restricted cash</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,650</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,503</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Deposit and other long-term assets</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,270</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,413</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:40pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">196,770&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">308,372&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Liabilities and stockholders' equity</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current liabilities&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accounts payable</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,170&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,238&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accrued expenses and other current liabilities</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16,362</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16,767</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lease liability, current portion</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10,324</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13,241</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:40pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total current liabilities</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28,856</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32,246</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lease liability, net of current portion</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">65,200</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">93,561</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other noncurrent liabilities</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,047</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:40pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total liabilities</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">94,056</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">126,854</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Stockholders' equity&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Common stock</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional paid-in capital</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">999,319</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">985,651</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accumulated other comprehensive loss</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(552)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,531)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:20pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accumulated deficit</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(896,063)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(802,612)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total stockholders' equity</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">102,714</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">181,518</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:40pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total liabilities and stockholders' equity</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">196,770&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">308,372&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(1) Derived from Adverum's annual audited consolidated financial statements.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.939%"><tr><td style="width:1.0%"></td><td style="width:49.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.547%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.552%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consolidated Statements of Operations</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(In thousands except per share data)</font></div></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">(Unaudited)</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Three months ended September 30,</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nine months ended September 30,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2023</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2022</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">License revenue</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,600&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:19pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating expenses&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20,740</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23,849</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">62,398</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">77,078</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13,789</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17,188</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39,035</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">46,117</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total operating expenses</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">34,529</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">41,037</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101,433</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">123,195</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Operating loss</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(34,529)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(41,037)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(97,833)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(123,195)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income, net</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,661</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">923</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4,437</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1,450</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss before income taxes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(32,868)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(40,114)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(93,396)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(121,745)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Income tax provision</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(17)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(17)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(55)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(55)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(32,885)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(40,131)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(93,451)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(121,800)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net loss per share &#8212; basic and diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.33)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.40)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(0.93)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1.23)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Weighted-average common shares outstanding - basic and diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100,999</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99,475</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100,693</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99,027</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>advm-20231109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8ba87662-ad53-413a-ac26-122ea970731c,g:b4d8d8ae-b05c-45ce-b683-71836c355ca9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20231109" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20231109">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20231109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20231109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.adverum.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>advm-20231109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8ba87662-ad53-413a-ac26-122ea970731c,g:b4d8d8ae-b05c-45ce-b683-71836c355ca9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_9b62bb6f-6004-4a6e-ad53-1e5cbe08f57c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5a3207a6-ebe3-47d8-8240-f98b71c8204c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b6beddd6-2bca-4cce-8f59-42a6f522d422_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3b82d80e-c727-44c3-ac3b-507e56fc7d80_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_eb3176bc-4d26-4a3f-89e9-35b72077725c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9fa371ce-39f0-4a99-a708-b394df448544_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_419d157b-9755-4d6a-a76f-cdbf615675ba_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2daa75aa-bef9-4519-9139-eea6fe004871_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d5d613ac-7372-4647-870a-7728e8a7211f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fed27409-9a0e-4c81-9c03-2cc937b30038_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4a7bf239-8fae-451e-b552-bd9e29c4bb1b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_bac8ed1d-3451-49a6-a8b2-f0dfc6aa8af4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_16647e36-00b9-43a4-b4f3-8414a2c37637_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_54ac6b3f-7e5a-4ad1-b10e-964a5914682c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d10cea3c-6c85-46a7-89a6-41d7d80ab899_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_37346d68-fde1-4c35-ba12-f27b13782168_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_36eaeb5d-5b29-45bb-aada-a5a81b26e98f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0b6b2c45-19b4-481f-b1c1-b848eb740595_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_beb24fe8-06df-41c3-852a-de22454fab14_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6019457c-7837-488a-9323-9a30dea97ba7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_26d5eaaa-3213-435c-bfd4-b17f944c1aaf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_778fec30-e439-4f0b-b26b-8eb0e41e93ed_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>advm-20231109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:8ba87662-ad53-413a-ac26-122ea970731c,g:b4d8d8ae-b05c-45ce-b683-71836c355ca9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/Cover" xlink:type="simple" xlink:href="advm-20231109.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_531f907e-b2f6-4bbf-a6aa-82307a8a23e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_DocumentType_531f907e-b2f6-4bbf-a6aa-82307a8a23e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4a3cf92e-f6da-4063-ac61-cc226b987944" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_DocumentPeriodEndDate_4a3cf92e-f6da-4063-ac61-cc226b987944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_df2a4103-efb5-4568-9fc7-03d44f2ca676" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityRegistrantName_df2a4103-efb5-4568-9fc7-03d44f2ca676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_527229e4-09fc-49a0-a28f-01e2c1881dd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_527229e4-09fc-49a0-a28f-01e2c1881dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b298a020-8181-4f59-93ec-82213829e7b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityFileNumber_b298a020-8181-4f59-93ec-82213829e7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_989f4bc8-44fd-46d0-9e1f-9061966e8407" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityTaxIdentificationNumber_989f4bc8-44fd-46d0-9e1f-9061966e8407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_283af256-6c21-4f5a-8e78-4a79668a0a39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityAddressAddressLine1_283af256-6c21-4f5a-8e78-4a79668a0a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9773614f-ce17-49d5-836d-21490bf896e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityAddressCityOrTown_9773614f-ce17-49d5-836d-21490bf896e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c938c445-97f1-4414-a264-f8cf4d554a71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityAddressStateOrProvince_c938c445-97f1-4414-a264-f8cf4d554a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5cefe1d8-7813-4fed-9ff5-64a3e9f93f72" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityAddressPostalZipCode_5cefe1d8-7813-4fed-9ff5-64a3e9f93f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fdf662d4-121e-451e-b547-9ecc8e25cbd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_CityAreaCode_fdf662d4-121e-451e-b547-9ecc8e25cbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a602e181-f758-4425-9d52-17b9c19bc8c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_LocalPhoneNumber_a602e181-f758-4425-9d52-17b9c19bc8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_0fc4d219-69cf-46af-89c8-45dff794ce17" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_WrittenCommunications_0fc4d219-69cf-46af-89c8-45dff794ce17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6eb9acf7-6bf5-41e5-8d3b-ec4370c5f783" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_SolicitingMaterial_6eb9acf7-6bf5-41e5-8d3b-ec4370c5f783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_06fbe267-d9ea-4eec-95b2-2eddf348e5fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_PreCommencementTenderOffer_06fbe267-d9ea-4eec-95b2-2eddf348e5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_585d857e-3b31-4dd6-83f2-7bda17dcec55" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_585d857e-3b31-4dd6-83f2-7bda17dcec55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_45b0940e-e476-49c8-9a0a-777b71f0fcec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_Security12bTitle_45b0940e-e476-49c8-9a0a-777b71f0fcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_66389409-7b4c-48bc-aa31-efe9e4a8a680" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_TradingSymbol_66389409-7b4c-48bc-aa31-efe9e4a8a680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_23c0f413-fa08-4ca9-a002-53816df9e0b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityCentralIndexKey_23c0f413-fa08-4ca9-a002-53816df9e0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f1275cfa-0b6f-4cde-8ab7-a6f3740ed4c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_EntityEmergingGrowthCompany_f1275cfa-0b6f-4cde-8ab7-a6f3740ed4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_05361ea7-cebe-43c6-bb72-59b6c778d0e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_AmendmentFlag_05361ea7-cebe-43c6-bb72-59b6c778d0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9cb33f7a-29e2-425f-aa24-78d0b060ceba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2482497c-5445-4d60-a927-dddcfb52f6e5" xlink:to="loc_dei_SecurityExchangeName_9cb33f7a-29e2-425f-aa24-78d0b060ceba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "? ?$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **3-+0 4444 %%%)F@!:*3-&: %HHHH ***3- "T4E+0 4444 %%%)0 M%)
MFEH **3-+0 4444 %%)FC(H 6BDI: "BBDR* %HHHH **2EH ***2@!:***
M"BBDH 6BBB@ HHHH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M.)^''[27A7XF^*)]#TQKB.Z4,T33( LRKU*UZTO2OSM_9%_Y+7HO_7"7_P!
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M\;8S@CZ5\1_M2?$;_A/OB==0P2[]-TH&T@QT+ _.P^IX_ 5[5^P?QX7\3?\
M7['_ .@&NMT5&GS'QF&SN>)S1X6-N17_  /J44ZFX/>G5R'V@M%%% !1110
M4444 %%%% !1110 4444 %(W2BD9AB@#RW]HKXD+\-_AM?W43A=0NE^S6JYP
M=[<9'T'-?.G[&OPU;Q)XIO/%6H1F2VL<I"SCAYFZG\ :Q/VJ/'D_Q(^*<7A[
M3"T]KITGV2)$Y#W#'#'\#Q^!K["^$'@&'X;^ =+T:-1YT<8>=A_%(1EC^?\
M*NQ_NJ?FSX6"_M;-')ZTZ7YGQ?\ M >#[OX._&)-6TU6AMKB87]JR\ ,#EE_
MSZU]O_#?QE;>/O!NF:W;,K)<PJ7 _A?^(?G7 _M1_#<>/_AO=301[M2TP&Y@
MXY( ^9?R_E7SA^SK^T9;?"/0=7TK68;F[M]WG6<4(!(?^)3GH.]-Q]M336YG
M3JPR3,9PJ.U.>J/O,XVYS7!>/OC=X.^&ZD:SK$0NNUG#^\F/_ 1T_'%?(/CC
M]JCQW\2KPZ9H,<FD6\QVI:Z<IDN7![%ASGZ8K0^'O['WBWQI*FH>)KDZ%:R'
M<RRGS;J3/MG"_B<^U2J*CK-G94SVKB9>RRZFY/N]CZIOOB!!XP^%EUXB\*SM
M<))$WELJD.A!PP([$<UX]\+=?UEO&UBD-S<7 F?$Z,Q8%>Y->[^ _ FC_"WP
M?%HNG;DTZV#.\EPP+,3RS,:YSX<?%;X?>-/$=_IWAF: ZE%EGVVYC\T X+*2
M!N&:^ SCA_$9EF%'&4*[C&GNNY^@8#-J>$PKPV*@O:3_ #/3AFGTVES[5]GJ
M<(C@,", CN*^//VP/@=;:7 ?&VB6XA1G":A!&N%YZ2#\>#7V'7,_$S18?$'@
M#7["<;HYK*48]PI(_4"MJ<W&2/'S3!PQN&E"2U6Q\\?L2_$^;4+.^\&WTID:
MS7[39%SSY1.&0>P//T-?0'Q4\$P?$/P'J^B3*";B%O*8C[L@Y4_F*^#_ -F+
M4I-'^./AP1L5\^22UD]P5)_FHK]'/O#FM:RY)W1X^0U7C<O=&KK:Z/S@^!'C
M"X^%/Q=L_MI:"(S&PO4;@#)QD_0X-?H]'(LJAT.58 @BO@S]L+X>_P#"(_$=
M=;M$,=EK"^:64<+,/O?GUKZC_9N^((^(/POTVXD???6B_9;CGG<HP#^(Q55E
MS)5$<N0U)83$5<NJ='='J58?C;Q-;^#?"NIZU=,%BLX&DY[D#@?B<5N-TKY9
M_;=^(/\ 9^AZ=X3MI,2WK?:+D*?^6:_=!^IK"G'FDD?39EBE@\+.L^BT]3YX
M^'^@7OQL^,5M#=%I#J%XUW=N><1 [F_H*_2>SM8[.UBMX5"11($11V & *^8
MOV(_AW_9_A^_\6W46)M0;R+8L.1$IY/XFOJ,9YK2O+WK+H>-P[A'1PSKU/BG
MK\CPW]LL?\65NS_T]0_^A5YK^P:?])\5_P"[%_,UZ3^V7_R1.\_Z^H?_ $*O
MFS]G/XY:7\%Y-9;4;"ZO?MH0(+7;\NW/7)%:P3E1:1Y>/KT\-G=.K5=DD?H-
M17S-_P -V>%_^@#JO_D/_P"*H_X;L\+_ /0 U7_R'_\ %5S^QJ=CZ/\ MS+_
M /GZCZ9I:^95_;J\*LZ[]#U5(\_,V$.T=SC=7T1X?UNU\3:+9ZI8R>;:7<2R
MQMT)!&:B5.4/B.["X_#8QM4)WL:7\-?FU\?O^2]^)/\ L()_):_27^&OS:^/
MO_)>_$O_ &$$_DM=&&^)GS7%/\"E_B/T4\/_ /(!T_\ Z]X__016C65X?N(O
M[!T\>8H_T>//(_NBM#[5%_SU3_OJN9I\ST/K:4X^SCKT)<U\X?MN:+:77PWL
MM2D1?M=K=JL38^8AA@BO=M<\6:-X;M&NM4U.UL;=1DR3RA1^IYKXB_:@^/=K
M\4KZVT;0R[Z)92;S.5P;B7H"H]!V]:VHQES)GS^?8NA#!SIR:<GHD>A_L&WD
MS:?XLM228$GA=?3<5.?Z5](?$;_D0?$/_7C-_P"@&O,/V2OAK=> ?AR;K48F
M@U'5I!<O&PP43&$!]\?SKT[XC?\ (@^(?^O&;_T T5&G4N7EU*='*E"IORO\
MCX2_9%_Y+7HG_7"7_P! -?HE7YW?LB_\ELT3_KA+_P"@&OT1JL1\2.'A;_=)
M?XF+1117*?9G@/[:7_)'V_Z_(_ZUPG[!?^I\6?[\'\FKN_VTO^2/M_U^1_UK
MA/V"S^Y\6?[\'\FKLC_!9\+B/^1_3]#ZQO/^/.?_ '&_E7Y;-H=QXD\>7NF6
M@!N;B^G6,'G)WMQ7ZDWW_'G/_N'^5?G#\*QN_:#TH8'.M..?^NC4\.[)LSXH
MIJM.A3;W9V?[(/Q";P;\1)= O6,-IJF8=K'A)U/']17WAVK\]?VDO!4_PO\
MBX^I6"M!;7KB_M77@+)G+ ?CS^-?;/PF\<0_$/P'I6MQ,&>:("8?W9!PP^N?
MYU-:*=IHZ.'ZTJ,JF7U=X/3T.RZUYM\?_B(GPW^&NJ:@CA;V9?L]JN>3(PQG
M\!S^%>D# 6OA3]LCXBMXI\=Q>'K1]]II(VLJG(>9L9_+@5E2AS2/8SK&?4\)
M*4?B>B^9X='H=Y?:'?:XP)M8+A('D;JTCY.!^ .:^M_V#L_\(SXF_P"OR/\
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MQ9N;/<?X3]]?P//XU]:"N*K>,K,^[RBM2Q&$A.G&W1^IB>.O^1,US_KRF_\
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M'B:68T^CLS]$[JYCL[>6>5@D<:EV)Z  9S7YO^/M6O?CA\:IEM"TGV^[%I;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140196014828720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  09,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Cardinal Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>advm-20231109_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20231109.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2023-11-09</startDate>
            <endDate>2023-11-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501756</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-11-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36579</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">100 Cardinal Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">656-9323</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
M]H!I5P=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " #V@&E77=RKX.\    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #V@&E7F5R<(Q &
M  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( /: :5>V:9*J.00  &L0   8              " @0X(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #V@&E7GZ ;\+$"
M  #B#   #0              @ %]#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( /: :5>7BKL<P    !,"   +              "  5D/  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( /: :5>JQ"(6,P$  "("   /              "
M 4(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #V@&E7)!Z;HJT   #X
M 0  &@              @ &B$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #V@&E799!YDAD!  #/ P  $P              @ &'
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #1$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="advm-20231109.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="advm-20231109.htm">advm-20231109.htm</File>
    <File>advm-20231109.xsd</File>
    <File>advm-20231109_lab.xml</File>
    <File>advm-20231109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "advm-20231109.htm": {
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20231109",
   "dts": {
    "inline": {
     "local": [
      "advm-20231109.htm"
     ]
    },
    "schema": {
     "local": [
      "advm-20231109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20231109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20231109_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "report": {
    "R1": {
     "role": "http://www.adverum.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231109.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "advm-20231109.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.adverum.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-038227-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-038227-xbrl.zip
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M@QKCP(-V7,4R]AKMG3O[.-\0N^WFZ0J/YJS>XC@D]QY8![>;C,$84+ +>$@
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M'>0/1$HJVE:G\PYA':5UPKYVW6X%P^7:?S];0"?8;_5B] 102P,$%     @
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MHO,]]HGC(I^G(BUU8? KTUI,V7Q&8"QA$'$01T&@!_60Z501)D!(GH0P"*.
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M3KG8#MO^F@^,=T8KQ8F+A2"2"4=<X(HPSL%93;5@X=O%@9?11.. >%H$(HN
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M\\XD^XX".KI]S[6(-AXNHF6.U=H<JU)UW5]U?0(!^:"B/>DGDH]ZM9<*B,5
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MJP-EF6*.C#0:Q4Q]LYC)$8C%HC++5+"A:+XZ46F)Q < 'Z:TKN87D:;I(B8
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M,#(S,3$P.2YX<V102P$"% ,4    " #V@&E7DDLF<T@*   :70  %0
M        @ &W$0  861V;2TR,#(S,3$P.5]L86(N>&UL4$L! A0#%     @
M]H!I5W@6V)2J!@  W#   !4              ( !,AP  &%D=FTM,C R,S$Q
M,#E?<')E+GAM;%!+ 0(4 Q0    ( /: :5=7MR2N>1T  )DR 0 >
M      "  0\C  !E>&AI8FET.3DQ7S$Q,#DR,W!R97-S<F5L92YH=&U02P4&
2      4 !0!0 0  Q$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
